ClinicalTrials.govpublic full text
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
solid tumors, egfr exon 20 insertion mutations, nsclc, egfr-mutated nsclc, egfr mutations, egfr exon20, oric-114, amivantamab, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 969230
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.